Edit

Cusack

Crystal selection for X-ray diffraction experiments.

Investigating the structure and mechanisms of coronavirus biomolecules

While global research on coronaviruses has shed light on the function of many SARS-CoV-2 proteins, the role of some crucial components remains unknown. Researchers at EMBL Grenoble will use a range of structural biology methods to try to solve some of the puzzles of the molecular mechanics of…

By Adam Gristwood

Science

The Influenza virus

Understanding the influenza virus

The infectious disease commonly known as flu is caused by the influenza virus. It spreads around the world in seasonal outbreaks, causing millions of infections and hundreds of thousands of deaths each year. Stephen Cusack, Head of EMBL Grenoble, has been studying different aspects of the influenza…

By Fabian Oswald

Science

Influenza polymerase (light cyan) in the process of synthesising messenger RNA (slate blue).

Paving the way for new flu drugs

Snapshots of the flu virus replication machine in action

By Mathias Jäger

Science

Mutations at the amino acid shown in orange (isoleucine 38) lead to reduced susceptibility to the drug. IMAGE - Stephen Cusack, EMBL

Flu’s response to new drug explored

EMBL scientists investigate how influenza virus responds to new drug treatment

By Iris Kruijen

Science

In this representation of influenza polymerase, a molecule (white) that strongly inhibits the enzyme’s activity is shown bound to the region of the enzyme (red) that usually binds the cap section of mRNA. IMAGE: EMBL/Cusack Group

Futures: Unravelling influenza

ERC grantee Stephen Cusack shares his vision for the next ten years

By Edward Dadswell

Science

How flu steals your RNA

Understanding how the flu virus steals host RNA offers hope of new drugs

By Rosemary Wilson

Science

New Crystallography platform inaugurated

A new crystallography platform in Grenoble opens the door to new technological developments

By Isabelle Kling

Lab Matters

New drug candidate unleashed for TB

EMBL researchers help to design a lead compound active against four different pathogens

By Margaux Phares

Science

Opinion: 2006, a year of champagne

Stephen Cusack looks back on the early days of his collaboration with Anacor developing anti-infectives

By Guest author(s)

Lab Matters

Opinion: A journey from bench to clinical trials

Andrés Palencia on the design of compounds that may help fight drug-resistant TB and more

By Guest author(s)

Lab Matters

EMBLetc.

Read the latest Issues of our magazine - EMBLetc.

Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.

EMBLetc. archive
Edit